Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB928 + doxorubicin
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
AB928 + doxorubicin is a combination therapy under investigation for cancer treatment. AB928 (etrumadenant) is a selective, small-molecule dual antagonist of the adenosine A2a and A2b receptors. It blocks the immunosuppressive effects of high adenosine concentrations in the tumor microenvironment, thereby enhancing anti-tumor immune responses. Doxorubicin is an anthracycline chemotherapy agent that intercalates DNA and inhibits topoisomerase II, leading to cytotoxicity in rapidly dividing cells. The combination aims to leverage both direct cytotoxic effects from chemotherapy and immune modulation from adenosine receptor blockade. This regimen has been studied particularly with pegylated liposomal doxorubicin in solid tumors such as triple-negative breast cancer and ovarian cancer[1][2][3][4].
- Brand names
- Doxil
- Other names
- AB928 + pegylated liposomal doxorubicinetrumadenant + doxorubicin
02
Targets
ADORA2B (Adenosine A2B receptor)ADORA2A (Adenosine A₂A Receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on AB928 + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB928 + doxorubicin.